Efficacy of Cannabidiol in Pediatric Patients: Postmarket Experience at a Single Center

Abstract

The purpose of this research was to determine the postmarket efficacy and safety of cannabidiol in pediatric patients with Lennox–Gastaut's syndrome (LGS), Dravet's syndrome (DS), and other drug-resistant epilepsy (DRE). This was a single-center, retrospective cohort study in pediatric patients who received prescription cannabidiol at a single center. The primary outcome was the reduction in seizure frequency of all seizure types as measured by the Engel outcome scale at 3 months after initiation of cannabidiol. Thirty-six patients were included. The most common outcome in all three groups was an Engel Class III outcome 3 months following initiation of cannabidiol. Most patients in all groups experienced some clinical benefit and only 33% of patients experienced no clinical benefit. The maximum tolerated dose of cannabidiol at 3 months ranged from 5 to 31 mg/kg/d with a median of 17.9, 13.2, and 18.0 mg/kg/d in the LGS, DS, and DRE (other) groups, respectively. Eight patients discontinued cannabidiol at 3 months and only two patients were hospitalized after initiation of therapy. Seventy-five percent of patients did not report any adverse side effects. Based on the Engel outcome scale utilized within this study, pediatric patients with LGS, DS, and DRE (other) may experience a worthwhile improvement in seizure frequency while on cannabidiol. Further studies are needed to determine the long-term efficacy and safety of cannabidiol and discern predictors of response to therapy.

Keywords

cannabidiol - Dravet's syndrome - drug-resistant epilepsy - Lennox–Gastaut's syndrome - pediatric - seizure

Publikationsverlauf

Eingereicht: 01. März 2023

Angenommen: 15. März 2023

Artikel online veröffentlicht:
12. April 2023

• References

• 1 Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy—United States, 2015. MMWR Morb Mortal Wkly Rep 2017; 66 (31) 821-825
• 2 Sheng J, Liu S, Qin H, Li B, Zhang X. Drug-resistant epilepsy and surgery. Curr Neuropharmacol 2018; 16 (01) 17-28
• 3 Kwan P, Arzimanoglou A, Berg AT. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51 (06) 1069-1077
• 4 U.S. Food & Drug Administration.. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Updated June 25, 2018. Accessed December 7, 2022, at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
• 5 Arzimanoglou A, Brandl U, Cross JH. et al; The Cannabinoids International Experts Panel, Collaborators. Epilepsy and cannabidiol: a guide to treatment. Epileptic Disord 2020; 22 (01) 1-14
• 6 Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord 2020; 22 (S1): 10-15
• 7 Devinsky O, Marsh E, Friedman D. et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016; 15 (03) 270-278
• 8 Thiele EA, Marsh ED, French JA. et al; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018; 391 (10125): 1085-1096
• 9 Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017; 377 (07) 699-700
• 10 Devinsky O, Patel AD, Cross JH. et al; GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018; 378 (20) 1888-1897
• 11 Thiele E, Marsh E, Mazurkiewicz-Beldzinska M. et al. Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia 2019; 60 (03) 419-428
• 12 Szaflarski JP, Bebin EM, Comi AM. et al; CBD EAP study group. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia 2018; 59 (08) 1540-1548
• 13 Laux LC, Bebin EM, Checketts D. et al; CBD EAP study group. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res 2019; 154: 13-20
• 14 Engel J, Van Ness PC, Rasmussen TB, Ojemann LM. Outcome with respect to epileptic seizures. In: Engel Jr J. ed. Surgical Treatment of the Epilepsies. Vol. 2. New York: Raven Press; 1993: 609-621
• 15 Durnford AJ, Rodgers W, Kirkham FJ. et al. Very good inter-rater reliability of Engel and ILAE epilepsy surgery outcome classifications in a series of 76 patients. Seizure 2011; 20 (10) 809-812
• 16 Epidiolex.. Package insert. Carlsbad, CA: Greenwich Biosciences, Inc.; 2018